Plasminogen Therapy for Pink Eye

Overseen By Simona Meier, BSc, ACRP-CP.

Age: < 65

Sex: Any

Trial Phase: Academic

Sponsor: University of Saskatchewan

Disqualifiers: Age 18 or older, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 2 to 6 months

Trial Summary

What is the purpose of this trial?

This trial uses small amounts of donated blood plasma applied to the eyes to treat patients with recurrent eye lesions caused by congenital plasminogen deficiency. The plasma contains a protein that helps dissolve and prevent these lesions.

Eligibility Criteria

This trial is for children under 18 with Ligneous Conjunctivitis, a type of pink eye caused by plasminogen deficiency. They must have pseudomembranous lesions and low serum plasminogen levels (<50%). It's not for adults or those without this specific condition.

Inclusion Criteria

I have eye inflammation due to low plasminogen levels.

I have been diagnosed with plasminogen deficiency.

I am under 18 years old.

Exclusion Criteria

I do not have a plasminogen deficiency.

I do not have eye symptoms due to plasminogen deficiency.

I am 18 years old or older.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Topical administration of aliquoted allogenic plasma to the affected eye every 1-5 hours daily

2 to 6 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

24 months

Treatment Details

Interventions

• Aliquoted Allogeneic Donor Plasma

Trial Overview The study tests the use of donor plasma applied directly to the eyes of kids with Ligneous Conjunctivitis. The treatment lasts 2-6 months based on how severe the disease is and how well the patient responds, with possible re-treatment if symptoms return.

Participant Groups

Group I: Intervention arm (aliquoted plasma application into the conjunctiva) Experimental Treatment 1 Intervention

This is the only arm of the study. The intervention is administration of aliquoted plasma provided by Canadian Blood Services in eye droppers (3 ml aliquots in 7 ml vials) in the patient's conjunctiva. The duration of therapy can be 2 to 6 months depending on response The intra-ocular drops will be administered every 1-5 hours daily in the affected eye based on disease severity and may be repeated

Who Is Running the Clinical Trial?

University of Saskatchewan

Lead Sponsor

Trials

261

Recruited

156,000+

Canadian Blood Services

Collaborator

Trials

24

Recruited

39,200+